It’s al­most the end of the road for Fresh Tracks as board sup­ports liq­ui­da­tion

It ap­pears to be al­most clos­ing time for Fresh Tracks Ther­a­peu­tics, as its board ap­proves plans to liq­ui­date and dis­solve the com­pa­ny. The biotech plans to meet with share­hold­ers in the fourth quar­ter to seek con­sent on the plan.

Most em­ploy­ees will be laid off by ear­ly Oc­to­ber, apart from cer­tain staff mem­bers like con­sul­tants and ad­vi­sors who will close up shop. Pres­i­dent and CEO An­drew Sklaw­er will ex­it “with­out cause” by Oct. 2, per an SEC fil­ing. Al­bert Mar­chio II, the com­pa­ny’s chief fi­nan­cial of­fi­cer, will ex­tend his re­mit as the new CEO, as well as sec­re­tary, di­rec­tor and chair­man of the board.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER